Therefore, the AMPK-induced threonine phosphorylation of FASN likely did not play a role in the regulation of FASN activity by the relatively low dose of lapatinib or C75 we used in HER2-positive breast cancer cells. The gene discussed is ERBB2; the disease is breast cancer.